Please login to the form below

Not currently logged in
Email:
Password:

Czech biotech Sotio selects Chiltern International

UK CRO will work on late-stage trials for its prostate cancer therapy

UK headquartered contract research organisation (CRO) Chiltern International has been appointed by Czech biotech Sotio to carry out phase III clinical trials.

Under the agreement, the CRO will provide full-service management of the phase III trials, entitled Viable, which will involve 126 treatments for 750 prostate cancer patients from across Europe.

The trials will assist the biotech company's development of Active Cellular Immunotherapy (ACI), which focuses on cancer and autoimmune disease treatments - specifically, therapies using an immunotherapy platform based activated dendritic cells.

Chiltern will also be responsible for processing the data obtained during the clinical evaluation.

"I am very pleased that we have been selected to manage this high profile trial," said Chiltern CEO Dr Jim Esinhart.

"I believe it underscores the strengths and expertise of our global oncology therapeutic area team. We look forward to working in close partnership with Sotio deliver a quality outcome."

Viable will be a global clinical trial, tracking a total of 1,170 prostate cancer patients from Europe and the US.

19th March 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics